Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology Kidney Week 2024
| INZY Stock | USD 1.30 0.05 3.70% |
Slightly above 62% of Inozyme Pharma's investor base is looking to short. The analysis of the overall investor sentiment regarding Inozyme Pharma suggests that many traders are alarmed. Inozyme Pharma's investing sentiment can be driven by a variety of factors including economic data, Inozyme Pharma's earnings reports, geopolitical events, and overall market trends.
Inozyme |
BOSTON, Oct. 17, 2024 -- Inozyme Pharma, Inc. , a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that interim data from the Companys ongoing Phase 1 SEAPORT 1 of INZ-701 in patients with end-stage kidney disease receiving hemodialysis will be presented during a poster session at the American Society of Nephrology AS
Read at finance.yahoo.com
 |
Inozyme Pharma Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Inozyme Pharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Inozyme Pharma Fundamental Analysis
We analyze Inozyme Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Inozyme Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Inozyme Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
EBITDA
EBITDA Comparative Analysis
Inozyme Pharma is rated third overall in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Inozyme Pharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Inozyme Pharma stock to make a market-neutral strategy. Peer analysis of Inozyme Pharma could also be used in its relative valuation, which is a method of valuing Inozyme Pharma by comparing valuation metrics with similar companies.
Peers
Inozyme Pharma Related Equities
| TERN | Terns Pharmaceuticals | 4.94 | ||||
| DAWN | Day One | 1.14 | ||||
| AMLX | Amylyx Pharmaceuticals | 0.87 | ||||
| MREO | Mereo BioPharma | 2.34 | ||||
| HOOK | Hookipa Pharma | 2.45 | ||||
| INZY | Inozyme Pharma | 3.70 | ||||
| XFOR | X4 Pharmaceuticals | 3.92 |
Additional Tools for Inozyme Stock Analysis
When running Inozyme Pharma's price analysis, check to measure Inozyme Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inozyme Pharma is operating at the current time. Most of Inozyme Pharma's value examination focuses on studying past and present price action to predict the probability of Inozyme Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inozyme Pharma's price. Additionally, you may evaluate how the addition of Inozyme Pharma to your portfolios can decrease your overall portfolio volatility.